Glenmark Pharma Q2 FY27 Revenue Up 20% YoY to ₹42,473 Million
Glenmark Pharmaceuticals announced its financial results for the second quarter ended September 30, 2026. Consolidated revenue grew approximately 20% YoY on a like-for-like basis, reaching ₹42,473 million (USD 444.5 million). EBITDA stood at ₹8,638 million with a margin of 20.3%. Adjusted Profit After Tax (PAT) was ₹4,852 million (11.4% margin), while reported PAT was ₹2,638 million (6.2% margin). The company highlighted strong performance in India (14% YoY growth), North America (31% YoY core business growth), Europe (6.2% YoY), and Emerging Markets (33.2% YoY). The Chairman & Managing Director expressed confidence in meeting FY27 guidance, citing growth drivers and advancements in the oncology pipeline.
Key Highlights
- Consolidated revenue grew 20% YoY to ₹42,473 million on a like-for-like basis.
- EBITDA margin reported at 20.3% with ₹8,638 million.
- India formulations revenue grew 14% YoY.
- North America core business saw 31% YoY growth.
- Oncology pipeline advancements noted, with first launch expected by FY27.
Price Impact
More from GLENMARK